Last modified: September 29, 2021
Quick Facts
  • Expertise:
    Peritoneal Mesothelioma
    Gastrointestinal Malignancies
    Surgical Oncology
    Cytoreductive Surgery
    HIPEC
  • Certifications:
    American Board of Surgery
    American Society of Abdominal Surgeons
    Cornell University Medical College
    National Institutes of Health/National Cancer Institute
    Brigham and Women’s Hospital (Residency)
    Massachusetts General Hospital (Fellowship)

About Dr. Sugarbaker

Dr. Sugarbaker is chief of the Peritoneal Surface Malignancy Program and director of the Center for Gastrointestinal Malignancies at the MedStar Washington Hospital Center in Washington, D.C. He is the general secretary for the Peritoneal Surface Oncology Group International (PSOGI). This is an effort to develop treatment centers for peritoneal metastases and mesothelioma around the globe.

Sugarbaker has been the driving force behind the development of the cytoreductive surgery/hyperthermic intraperitoneal chemotherapy procedure that specialists are using today to effectively treat peritoneal mesothelioma.

Many of his colleagues refer to it as the “Sugarbaker Procedure,” which has become the standard treatment for several abdominal cancers that spread to the surfaces of the abdomen and pelvis.

The procedure has been credited with extending the lives of peritoneal mesothelioma patients, giving hope to those with this aggressive cancer who once had none. The 10-year survival rate of his most recent group of 36 surgical patients was 75%.

As an international expert on surgical oncology, Sugarbaker has lectured extensively, both within the U.S. and abroad, helping those around the world. He shares his expertise as a contributing writer for The Mesothelioma Center, the nation’s most trusted mesothelioma resource.

“He is a tireless innovator and one of the legends of our time,” said Dr. Brendan Moran, surgical oncologist at the Peritoneal Malignancy Institute at Basingstoke Hospital in the U.K. “I consider Paul Sugarbaker the global leader in surgical oncology.”